Dividends & Buybacks ·
Gossamer Bio, Inc. filed a Certificate of Amendment to its Charter on September 10, 2026, effecting a 1-for-80 reverse…
GOSSGossamer Bio, Inc.
Gossamer Bio, Inc. filed a Certificate of Amendment to its Charter on September 10, 2026, effecting a 1-for-80 reverse stock split of its common stock and reducing authorized shares from 4 billion to 50 million. The transaction became effective at 11:59 p.m. Eastern Time on September 10, 2026, with split-adjusted trading commencing on the Nasdaq Global Select Market on September 11, 2026. Fractional shares are rounded up to the nearest whole share rather than being cashed out. Convertible notes and warrants were proportionately adjusted to reflect the new ratio. The company states this action is intended to help regain compliance with Nasdaq's minimum bid price requirement by October 5, 2026. Gossamer Bio operates in the biopharmaceutical industry, developing treatments for pulmonary hypertension.